Intec Pharma Ltd (NASDAQ:NTEC) shares traded up 10.4% during mid-day trading on Monday . The company traded as high as $5.82 and last traded at $5.65, with a volume of 86,693 shares traded. The stock had previously closed at $5.12.

A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded Intec Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Maxim Group reiterated a “buy” rating and issued a $9.00 target price on shares of Intec Pharma in a research note on Tuesday, April 5th.

The firm’s 50-day moving average is $4.60 and its 200 day moving average is $4.12. The company’s market cap is $63.54 million.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.